These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36574187)

  • 21. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
    Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
    Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma.
    Sadot E; Doussot A; O'Reilly EM; Lowery MA; Goodman KA; Do RK; Tang LH; Gönen M; D'Angelica MI; DeMatteo RP; Kingham TP; Jarnagin WR; Allen PJ
    Ann Surg Oncol; 2015 Oct; 22(11):3512-21. PubMed ID: 26065868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort.
    Pietrasz D; Marthey L; Wagner M; Blanc JF; Laurent C; Turrini O; Raoul JL; Terrebonne E; Hentic O; Trouilloud I; Coriat R; Regenet N; Innominato P; Taieb J; Cunha AS; Bachet JB
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1196-205. PubMed ID: 26271395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Locally advanced anaplastic pancreatic adenocarcinoma with initial response to FOLFIRINOX and rapid progression after five months.
    Shinagare AB; Ramaiya NH; Bellizzi AM; Mayer RJ
    Pancreatology; 2012; 12(1):35-8. PubMed ID: 22487471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature.
    Valeri S; Borzomati D; Nappo G; Perrone G; Santini D; Coppola R
    Pancreatology; 2014; 14(5):425-30. PubMed ID: 25278312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A case of metastatic pancreatic adenocarcinoma with prolonged survival after combination of neoadjuvant FOLFIRINOX therapy and synchronous distal pancreatectomy and hepatectomy.
    Neofytou K; Giakoustidis A; Smyth EC; Cunningham D; Mudan S
    J Surg Oncol; 2015 May; 111(6):768-70. PubMed ID: 25556724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma.
    Farshadi EA; Chang J; Sampadi B; Doukas M; Van 't Land F; van der Sijde F; Vietsch EE; Pothof J; Koerkamp BG; van Eijck CHJ
    Clin Cancer Res; 2021 Dec; 27(23):6602-6612. PubMed ID: 34580113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX.
    Tanaka M; Heckler M; Mihaljevic AL; Sun H; Klaiber U; Heger U; Büchler MW; Hackert T
    Eur J Surg Oncol; 2019 Aug; 45(8):1453-1459. PubMed ID: 30981446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.
    Moorcraft SY; Khan K; Peckitt C; Watkins D; Rao S; Cunningham D; Chau I
    Clin Colorectal Cancer; 2014 Dec; 13(4):232-8. PubMed ID: 25442814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma.
    van Eijck CWF; de Koning W; van der Sijde F; Moskie M; Groot Koerkamp B; Homs MYV; van der Burg SH; van Eijck CHJ; Mustafa DAM
    Eur J Cancer; 2023 Mar; 181():119-134. PubMed ID: 36652890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pancreatic mucinous cystadenocarcinoma in a patient harbouring
    Di Marco M; Carloni R; De Lorenzo S; Mosconi C; Palloni A; Grassi E; Filippini DM; Ricci AD; Rizzo A; Di Federico A; Santini D; Turchetti D; Ricci C; Ingaldi C; Alberici L; Minni F; Golfieri R; Brandi G; Casadei R
    World J Gastrointest Oncol; 2020 Dec; 12(12):1456-1463. PubMed ID: 33362915
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surgical margin clearance and extended chemotherapy defines survival for synchronous oligometastatic liver lesions of the ductal adenocarcinoma of the pancreas.
    Safi SA; Fluegen G; Rehders A; Haeberle L; Fung S; Keitel V; Krieg A; Knoefel WT; Lehwald-Tywuschik N
    Int J Clin Oncol; 2021 Oct; 26(10):1911-1921. PubMed ID: 34132929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regimen.
    Garnier J; Ewald J; Marchese U; Gilabert M; Moureau-Zabotto L; Giovannini M; Poizat F; Delpero JR; Turrini O
    Eur J Surg Oncol; 2020 Aug; 46(8):1510-1515. PubMed ID: 32146053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [R0 Resection by Distal Pancreatectomy with En Bloc Celiac Axis Resection after Down-Staging by FOLFIRINOX Therapy in a Case of Pancreas Cancer--Report of a Case].
    Makino H; Kametaka H; Fukada T; Seike K; Koyama T; Hasegawa A
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):1644-6. PubMed ID: 26805124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathological complete response with FOLFIRINOX therapy for recurrence of pancreatic acinar cell carcinoma.
    Teramatsu K; Fujimori N; Murakami M; Yasumori S; Matsumoto K; Nakata K; Nakamura M; Koga Y; Oda Y; Ogawa Y
    Clin J Gastroenterol; 2024 Aug; 17(4):776-781. PubMed ID: 38761340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
    Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
    Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort.
    Kourie H; Auclin E; Cunha AS; Gaujoux S; Bruzzi M; Sauvanet A; Lourenco N; Trouilloud I; Louafi S; El-Hajjar A; Vaillant JC; Smith D; Touchefeu Y; Bachet JB; Pietrasz D; Taieb J
    Clin Res Hepatol Gastroenterol; 2019 Nov; 43(6):663-668. PubMed ID: 31029644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maintenance Olaparib for Germline
    Golan T; Hammel P; Reni M; Van Cutsem E; Macarulla T; Hall MJ; Park JO; Hochhauser D; Arnold D; Oh DY; Reinacher-Schick A; Tortora G; Algül H; O'Reilly EM; McGuinness D; Cui KY; Schlienger K; Locker GY; Kindler HL
    N Engl J Med; 2019 Jul; 381(4):317-327. PubMed ID: 31157963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.
    Dhir M; Zenati MS; Hamad A; Singhi AD; Bahary N; Hogg ME; Zeh HJ; Zureikat AH
    Ann Surg Oncol; 2018 Jul; 25(7):1896-1903. PubMed ID: 29761331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pancreatic Cancer with Liver Metastasis Treated with Radical Surgery after Chemotherapy].
    Katsura Y; Takeda Y; Ohmura Y; Sakamoto T; Inatome J; Naito A; Murakami K; Kagawa Y; Takeno A; Egawa C; Kato T; Tamura S
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):1975-1977. PubMed ID: 28133194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.